Related references
Note: Only part of the references are listed.Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
Christopher Jackson et al.
MEDICAL DECISION MAKING (2017)
Accounting for Cured Patients in Cost-Effectiveness Analysis
Megan Othus et al.
VALUE IN HEALTH (2017)
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naive Patients with Advanced Melanoma in the United States
Jingshu Wang et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2017)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
Ioannis Karydis et al.
ONCOIMMUNOLOGY (2016)
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
Christina Giannopoulou et al.
PHARMACOECONOMICS (2015)
The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK
James Larkin et al.
PLOS ONE (2015)
The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study
Mark J. Rutherford et al.
JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION (2015)
WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
Felipe Ades et al.
ECANCERMEDICALSCIENCE (2015)
Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach
Adrian Bagust et al.
MEDICAL DECISION MAKING (2014)
Statistical issues and challenges in immuno-oncology
Tai-Tsang Chen
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Estimating and modeling the cure fraction in population-based cancer survival analysis
Paul C. Lambert et al.
BIOSTATISTICS (2007)
Share Paper
